CD79A and aneurysmal bone cyst: Exposure to CAL-101 reduced the viability of 2 ABC DLBCL lines (Ly10, TMD8) that have gain-of-function mutations targeting the BCR subunits CD79A (Ly10) or CD79B (TMD8) as well as the MYD88 L265P mutation (Figure 1A).